Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers

European Neuropsychopharmacology

Volumn 25, Issue 11, 2015, Pages 2049-2061

  Harmeier, Anja ^a   Obermueller, Stefan ^a   Meyer, Claas A ^a   Revel, Florent G ^a   Buchy, Daniele ^a   Chaboz, Sylvie ^a   Dernick, Gregor ^a   Wettstein, Joseph G ^a   Iglesias, Antonio ^a   Rolink, Antonius ^b   Bettler, Bernhard ^b   Hoener, Marius C ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA ARRESTIN 2; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; QUINPIROLE; RECEPTOR; RO 5166017; SULPIRIDE; TRACE AMINE ASSOCIATED RECEPTOR 1; TYRAMINE; UNCLASSIFIED DRUG; BETA ARRESTIN; DRD2 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; RETINA S ANTIGEN; TRACE AMINE-ASSOCIATED RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; FEMALE; GENE INACTIVATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN-FRAGMENT COMPLEMENTATION ASSAY; RAT; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; BRAIN; CELL MEMBRANE; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM; TRANSGENIC RAT; WISTAR RAT;

ANIMALS; ARRESTINS; BRAIN; CELL MEMBRANE; CHO CELLS; CRICETULUS; CYCLIC AMP; GENE KNOCKOUT TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; RATS, TRANSGENIC; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84947493395     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.08.011     Document Type: Article

References (48)

1. Baltoumas F.A., Theodoropoulou M.C., et al. Interactions of the alpha-subunits of heterotrimeric G-proteins with GPCRs, effectors and RGS proteins: a critical review and analysis of interacting surfaces, conformational shifts, structural diversity and electrostatic potentials. J Struct. Biol. 2013, 182(3):209-218.
2. Beaulieu J.M., Del'guidice T., et al. Beyond cAMP: the Regulation of Akt and GSK3 by dopamine receptors. Front. Mol. Neurosci. 2011, 4:38.
3. Beaulieu J.M., Gainetdinov R.R., et al. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007, 28(4):166-172.
4. Beaulieu J.M., Sotnikova T.D., et al. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122(2):261-273.
5. Beaulieu J.M., Sotnikova T.D., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U S A 2004, 101(14):5099-5104.
6. Berry M.D. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev. Recent Clin. Trials 2007, 2(1):3-19.
7. Bettler B., Kaupmann K., et al. Molecular structure and physiological functions of GABA(B) receptors. Physio. Rev. 2004, 84(3):835-867.
8. Borowsky B., Adham N., et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. U S A 2001, 98(16):8966-8971.
9. Bradaia A., Trube G., et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc. Natl. Acad. Sci. U S A 2009, 106(47):20081-20086.
10. Bunzow J.R., Sonders M.S., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 2001, 60(6):1181-1188.
11. Burchett S.A., Hicks T.P. The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Prog. Neurobiol. 2006, 79(5-6):223-246.
12. Espinoza S., Salahpour A., et al. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol. Pharmacol. 2011, 80(3):416-425.
13. Fuxe K., Marcellino D., et al. Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia. J. Neural. Transm. 2009, 116(8):923-939.
14. Gainetdinov R.R., Mohn A.R., et al. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001, 24(9):527-533.
15. Gassmann M., Bettler B. Regulation of neuronal GABA(B) receptor functions by subunit composition. Nat. Rev. Neurosci. 2012, 13(6):380-394.
16. Geurts A.M., Cost G.J., et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 2009, 325(5939):433.
17. Gould T.D., Einat H., et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 2004, 7(4):387-390.
18. Ittner L.M., Gotz J. Pronuclear injection for the production of transgenic mice. Nat. Protoc. 2007, 2(5):1206-1215.
19. Kang U.G., Seo M.S., et al. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 2004, 560(1-3):115-119.
20. Ledonne A., Federici M., et al. Trace amines depress D(2)-autoreceptor-mediated responses on midbrain dopaminergic cells. Br. J. Pharmacol. 2010, 160(6):1509-1520.
21. Leo D., Mus L., et al. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors. Neuropharmacology 2014, 81:283-291.
22. Li X., Rosborough K.M., et al. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol. 2007, 10(1):7-19.
23. Lindemann L., Ebeling M., et al. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 2005, 85(3):372-385.
24. Lindemann L., Hoener M.C. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol. Sci. 2005, 26(5):274-281.
25. Lindemann L., Meyer C.A., et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J. Pharmacol. Exp. Ther. 2008, 324(3):948-956.
26. Lodeiro M., Alen B.O., et al. The SHP-1 protein tyrosine phosphatase negatively modulates Akt signaling in the ghrelin/GHSR1a system. Mol. Biol. Cell 2011, 22(21):4182-4191.
27. Lodeiro M., Theodoropoulou M., et al. c-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and -dependent mechanisms. PLoS One 2009, 4(3):e4686.
28. Maggio R., Novi F., et al. Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. Parkinsonism Relat. Disord. 2008, 14(Suppl 2):S139-144.
29. Masri B., Salahpour A., et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc. Natl. Acad. Sci. U S A 2008, 105(36):13656-13661.
30. Maurice P., Guillaume J.L., et al. GPCR-interacting proteins, major players of GPCR function. Adv. Pharmacol. 2011, 62:349-380.
31. Maurice P., Kamal M., et al. Asymmetry of GPCR oligomers supports their functional relevance. Trends Pharmacol. Sci. 2011, 32(9):514-520.
32. Missale C., Fiorentini C., et al. The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. J. Recept. Signal Transduct. Res. 2010, 30(5):347-354.
33. O'Brien W.T., Klein P.S. Validating GSK3 as an in vivo target of lithium action. Biochem. Soc. Trans. 2009, 37(Pt 5):1133-1138.
34. Pei Y., Lee J., et al. Activation of the trace amine-associated receptor 1 prevents relapse to cocaine seeking. Neuropsychopharmacology 2014, 39(10):2299-2308.
35. Pin J.P., Neubig R., et al. International union of basic and clinical pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev. 2007, 59(1):5-13.
36. Reiter E., Ahn S., et al. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 2012, 52:179-197.
37. Revel F.G., Meyer C.A., et al. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology 2012, 37(12):2580-2592.
38. Revel F.G., Moreau J.L., et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl. Acad. Sci. U S A 2011, 108(20):8485-8490.
39. Revel F.G., Moreau J.L., et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol. Psychiatry 2012, 72(11):934-942.
40. Revel F.G., Moreau J.L., et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol. Psychiatry 2013, 18(5):543-556.
41. Richards J.G., Higgins G.A., et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J. Neurosci. 2003, 23(26):8989-9003.
42. Rolink A.G., Andersson J., et al. Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. Eur. J. Immunol. 1998, 28(11):3738-3748.
43. Shenoy S.K., Lefkowitz R.J. Beta-arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 2011, 32(9):521-533.
44. Thorn D.A., Zhang C., et al. The trace amine associated receptor 1 agonist RO5263397 attenuates the induction of cocaine behavioral sensitization in rats. Neurosci. Lett. 2014, 566:67-71.
45. Voon V., Pessiglione M., et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010, 65(1):135-142.
46. Whalen E.J., Rajagopal S., et al. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17(3):126-139.
47. Willi R., Schwab M.E. Nogo and Nogo receptor: relevance to schizophrenia?. Neurobiol. Dis. 2013, 54:150-157.
48. Xiao K., Sun J., et al. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc. Natl. Acad. Sci. U S A 2010, 107(34):15299-15304.